Clinical data | |
---|---|
Trade names | Edurant, Rekambys |
Other names | TMC278 |
AHFS/Drugs.com | Monograph |
MedlinePlus | a611037 |
License data |
|
Pregnancy category |
|
Routes of administration | By mouth, intramuscular |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Protein binding | 99.7% |
Metabolism | CYP3A4 |
Elimination half-life | tablets: 45 hours injection: 13–28 weeks |
Excretion | 85% via faeces, 6% via urine |
Identifiers | |
| |
CAS Number |
|
PubChem CID | |
DrugBank |
|
ChemSpider | |
UNII |
|
KEGG | |
ChEBI |
|
ChEMBL |
|
NIAID ChemDB | |
PDB ligand | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.224.394 |
Chemical and physical data | |
Formula | C22H18N6 |
Molar mass | 366.428 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Rilpivirine, sold under the brand names Edurant and Rekambys, is a medication, developed by Tibotec, used for the treatment of HIV/AIDS.[5][6] It is a second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) with higher potency, longer half-life and reduced side-effect profile compared with older NNRTIs such as efavirenz.[7][8]
Rekambys EPAR
was invoked but never defined (see the help page).